A detailed history of Quest Partners LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 22,074 shares of ETNB stock, worth $173,943. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,074
Previous 8,113 172.08%
Holding current value
$173,943
Previous $65 Million 151.36%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$7.36 - $9.66 $102,752 - $134,863
13,961 Added 172.08%
22,074 $163 Million
Q2 2024

Aug 06, 2024

BUY
$7.31 - $10.9 $41,126 - $61,323
5,626 Added 226.22%
8,113 $65 Million
Q1 2024

May 09, 2024

SELL
$8.13 - $13.77 $64,861 - $109,857
-7,978 Reduced 76.24%
2,487 $28.9 Million
Q4 2023

Feb 09, 2024

BUY
$6.66 - $16.03 $69,696 - $167,753
10,465 New
10,465 $117 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $366M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.